Novartis is responding to COVID-19 with the safety of our associates and patients we serve as our main concern. We are contributing to global research efforts, supporting local communities and ensuring stable supply and price of essential medicines. This US information center provides updates, guidance and other resources.
Novartis US response to COVID-19
Since the first reports of the COVID-19 outbreak globally and in the US, our primary concern at Novartis has and continues to be the health and safety of our associates and patients.